Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 3/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.37 |
| ▸ | DPP4 | P27487 | 6/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27863433 | 0.85 | CPN1 (0.39) | CPN1CPB2DPP4DPP8DPP7 | |
| SCHEMBL28434469 | 0.84 | DPP4 (0.39) | CPN1CPB2DPP4DPP8DPP7 | |
| SCHEMBL121181 | 0.81 | GPR119 (0.46) | GPR119 | |
| SCHEMBL170663 | 0.81 | GPR119 (0.46) | GPR119 | |
| SCHEMBL1295911 | 0.80 | CPN1 (0.41) | CPN1CPB2DPP4DPP8DPP7 | |
| SCHEMBL5993908 | 0.79 | CPN1 (0.39) | CPN1CPB2DPP4DPP8DPP7 | |
| SCHEMBL5994169 | 0.79 | CPN1 (0.39) | CPN1CPB2DPP4DPP8DPP7 | |
| SCHEMBL5993912 | 0.79 | CPN1 (0.39) | CPN1CPB2DPP4DPP8DPP7 | |
| SCHEMBL148385 | 0.78 | GPR119 (0.53) | DPP4GPR119ALDH1A1 | |
| SCHEMBL1576175 | 0.78 | GPR119 (0.53) | DPP4GPR119ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| EP-2406251-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| EP-2114931-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2011-11-02 | — | — | EP | disclosed |
| EP-2383270-A1 | Piperidine GPCR agonists | Prosidion Limited (GB) | 2011-11-02 | — | — | EP | disclosed |
| EP-2377864-A1 | Piperidine GPCR agonists | Prosidion Limited (GB) | 2011-10-19 | — | — | EP | disclosed |
| EP-2377863-A1 | Piperidine GPCR agonists | Prosidion Limited (GB) | 2011-10-19 | — | — | EP | disclosed |
| EP-2114933-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2011-09-07 | — | — | EP | disclosed |
| US-20110212939-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-01 | — | — | US | disclosed |
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| EP-2114935-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2011-07-20 | — | — | EP | disclosed |
| EP-2328867-A1 | HETEROCYCLIC GPCR AGONISTS | Prosidion Limited (GB) | 2011-06-08 | — | — | EP | disclosed |
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| WO-2010103334-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| US-20100105732-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| US-20100048632-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100048631-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100022591-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| WO-2010004347-A1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022591-A1 | PIPERIDINE GPCR AGONISTS | GPR119, GPR27, GLP1R | CPN1 3833/4885CPB2 4571/4885DPP4 410/4885 |
| US-20100048632-A1 | Piperidine GPCR Agonists | GPR119, GPR27, GLP1R | CPN1 3833/4885CPB2 4571/4885DPP4 410/4885 |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FFAR2, GPBAR1 | CPN1 3592/4885CPB2 1592/4885DPP4 407/4885 |
| US-20110178054-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GPR27 | CPN1 4242/4885CPB2 4274/4885DPP4 626/4885 |
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | GPR119, GPR27, GLP1R | CPN1 3073/4885CPB2 4171/4885DPP4 410/4885 |
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, DPP4, DPP9 | CPN1 1990/4885CPB2 803/4885DPP4 2/4885 |
| US-20100105732-A1 | PIPERIDINE GPCR AGONISTS | GPR119, GPR27, GLP1R | CPN1 3833/4885CPB2 4571/4885DPP4 410/4885 |
| US-20100048631-A1 | Piperidine GPCR Agonists | GPR119, GPR27, GLP1R | CPN1 3833/4885CPB2 4571/4885DPP4 410/4885 |
| US-20110212939-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GPR27 | CPN1 4180/4885CPB2 4305/4885DPP4 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.